Home/Stocks/Consumer Non-Cyclicals

Princes Group PLC

PRN.L·Consumer Non-Cyclicals·Market Cap £801m
Rank #74 of 280
Quantitative Model · 280 Stocks Analysed
£3.27
-27.22% YTD
52W: £2.94 - £4.98

Factor Analysis Summary

Editorial assessment generated from Princes Group PLC's live factor scores and sector positioning.

Based on Strategyland's proprietary 7-factor analysis, Princes Group PLC (PRN.L) currently holds an overall rank of #74 out of 280 FTSE 100 constituents, reflecting its weighted composite score across liquidity, valuation, profitability, solvency, asset efficiency, market trading, and technical dimensions.

Key strengths include asset efficiency, where it demonstrates highly efficient capital deployment, converting assets into revenue and returns effectively, and liquidity, where it demonstrates solid trading liquidity that should accommodate most institutional order sizes.

Areas requiring attention include profitability, where compressed margins and weak returns on equity weigh on the earnings profile, as well as market trading, where low relative volume or adverse volatility patterns may deter momentum-oriented investors.

Within the Consumer Non-Cyclicals sector, Princes Group PLC sits at composite rank #74, trailing the Consumer Non-Cyclicals peer average (rank 55). Among 7 Consumer Non-Cyclicals names in our coverage, it ranks above 2 peers and below 4.

The composite profile is weighed down by 3 below-average factor scores, with profitability (rank 274/280) representing the most significant drag on its #74 overall standing.

Strongest Factors

  • Asset Efficiency — Rank 61/280 (top quartile)
  • Liquidity — Rank 84/280 (above average)
  • Solvency — Rank 143/280 (middle of the pack)

Weakest Factors

  • Profitability — Rank 274/280 (below average)
  • Market Trading — Rank 268/280 (below average)

Score Analysis

Princes Group PLC is ranked #74 out of 280 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

171/280
Average Score
Liquidity
Good84/280
Valuation
Fair163/280
Profitability
Weak274/280
Solvency
Fair143/280
Asset Efficiency
Excellent61/280
Mkt Trading
Weak268/280
Technical
Weak202/280

1. Liquidity

Score: 84/280

How liquid is PRN and can it meet its short-term obligations?

0/6
liquidity criteria met
✗
Quick Ratio1.34x
Range: 0.8 - 1.3Rank 34/280
✗
Current Ratio2.00x
Range: 1.2 - 1.8Rank 72/280
✗
TTM Operating Cash Flow0.20x
Range: 0.8 - 1.5Rank 186/280
–
Liquidity Coverage RatioN/A
Range: N/A
✗
Intangible Asset Ratio0.04x
Range: 5 - 20Rank 95/280
✗
Cash-to-Debt Ratio1.82x
Range: 0.4 - 1.2Rank 42/280

Key Liquidity Metrics

Quick Ratio
1.34x
Sector: 0.8 - 1.3
Current Ratio
2.00x
Sector: 1.2 - 1.8

Overall Liquidity Rank

Rank within universe#84/280
Best (1)Worst (280)

2. Valuation

Score: 163/280

Is PRN undervalued compared to its peers and fair value metrics?

0/7
valuation criteria met
✗
FY27e P/E9.2x
Range: 15x - 28xRank 43/280
✗
FY26e P/E10.7x
Range: 15x - 28xRank 54/280
–
FY27e Net Div Yld (%)N/A
Range: 2.5 - 6.5Rank 207/280
–
Div Payout RatioN/A
Range: 35 - 65Rank 50/280
✗
Current EV/EBITDA6.0x
Range: 8.0x - 13.0xRank 73/280
✗
Current P/TBV1.19x
Range: 1.5x - 4.5xRank 96/280
✗
Current P/B1.06x
Range: 1.5x - 4.5xRank 109/280

Key Valuation Metrics

TTM P/E
Price-to-Earnings
17.4x
FY26e P/E
Forward estimate
10.7x
FY27e P/E
Forward estimate
9.2x
Current P/B
Price-to-Book
1.06x
Current P/TBV
Tangible Book Value
1.19x
Current EV/EBITDA
Enterprise Value
6.0x
FY26e EV/EBITDA
Forward estimate
3.1x
FY27e EV/EBITDA
Forward estimate
3.4x

Dividend

PRN does not currently pay a significant dividend.

—
No dividend data available for this stock.

3. Profitability

Score: 274/280

How profitable is PRN relative to its peers?

0/7
profitability criteria met
✗
TTM Profit Margin2.5%
Range: 5 - 11Rank 230/280
✗
T12 FCF Margin0.3%
Range: 8 - 15Rank 124/280
✗
FY27e RoE7.4%
Range: 8 - 20Rank 175/280
✗
FY26 EPS Growth-25.3%
Range: 3 - 8Rank 218/280
✗
FY27e EPS Growth-13.0%
Range: 4 - 8Rank 213/280
–
NIMN/A
Range: N/A
–
Expense RatioN/A
Range: 65 - 78
TTM Profit Margin
2.5%
Current RoCE
N/A
FY27e RoE
7.4%
T12 FCF Margin
0.3%

EPS Growth

4. Solvency

Score: 143/280

How strong is PRN's balance sheet and financial position?

0/6
solvency criteria met
✗
Debt/Eqt0.25x
Range: 0.3x - 0.7xRank 103/280
–
Interest Coverage RatioRank 226
Range: 4x - 10xRank 226/280
✗
Net Leverage Ratio-1.18x
Range: 1.0x - 2.0xRank 13/280
–
Altman Z-Score (Manufacturing)4.12
Range: <1.10 - >2.60Rank 138/280
–
Z-Score (Non Manufacturing)Rank 151
Range: <1.10 - >2.60Rank 151/280
–
CapAdeq Ratio Tier1N/A
Range: N/A

Key Solvency Metrics

Debt/Eqt
0.25x
Net Leverage Ratio
-1.18x
Interest Coverage
Rank 226
T12 FCF Margin
0.3%

Altman Z-Score

4.12
Safe Zone
01.812.995+

5. Asset Efficiency

Score: 61/280

How efficiently does PRN deploy its assets and intellectual capital?

3/5
asset efficiency criteria met
–
Efficiency RatioN/A
Range: N/A
✓
TTM Asset Turnover Ratio1.10x
Range: 0.8x - 1.5xRank 45/280
✓
TTM CAPEX/Sales3.7%
Range: 2 - 5Rank 112/280
✓
Working Capital Turnover4.77x
Range: 4x - 10xRank 86/280
–
R&D/Sales FY27eN/A
Range: 1.0 - 3.0

Overall Asset Efficiency Rank

Rank within sector peers#61/280
Best (1)Worst (280)

6. Market Trading

Score: 268/280

How liquid and actively traded is PRN?

1/2
market trading criteria met
✗
Intraday Sentiment (%)17.0%
Range: 30 - 70Rank 203/280
–
10D-Avg v/s 3M-Avg Vol53%
Range: N/ARank 100/280
✓
Avg Directional Index 30D21.4
Range: 010 - 35Rank 120/280
–
Parabolic SAR310.00
Range: N/ARank 202/280
–
Stock Rating RankRank 100
Range: N/ARank 100/280
Market Cap
£800,978,271
Enterprise Value
£553,985,181

Trading Volume

7. Technical

Score: 202/280

What do the technical indicators say about PRN?

0/5
technical criteria met
–
CMP v/s 52-WH-34.2%
£4.98£2.94
-34.2%CMP: £3.27
Range: N/ARank 260/280
–
CMP v/s 52-WL11.2%
£4.98£2.94
+11.2%CMP: £3.27
Range: N/ARank 58/280
–
RSI 14D46.7
046.7 - Bearish100
Range: N/ARank 50/280
–
MA50 - MA200Bearish
£3.22-0.40£3.62
Range: N/ARank 244/280
–
MACD Rank-0.56
Death Cross
MACD: -0.56
Range: N/A

RSI (14 Day)

46.7
Bearish
0 (Oversold)50100 (Overbought)

Moving Averages

50 SMA£3.22
200 SMA£3.62
SignalDeath Cross (Bearish)
MACD-0.56

Risk Metrics

Beta
N/A
3-Yr Std Dev
N/A
5-Yr Std Dev
N/A

Peer Comparison

How does PRN compare to other Consumer Non-Cyclicals stocks?

Overall Rank Comparison

Factor Score Comparison

StockRankLiquidityValuationProfitabilitySolvencyMkt TradingTechnical
PRN#7484163274143268202
ULVR.L#8131197141224108178
ANEA.L#23897815223152141
CCH.L#6111922615514170130
IMB.L#7117271110229107261
DGE.L#8148177162198137115
BATS.L#8787101129181131274
Sponsored
Healthcare Discovery Monitor
Live
Healthcare Discovery Monitor
Healthcare Discovery Monitorby StrategyLand

Catch Healthcare Events Before the Market Moves

SEC filings, FDA approvals, clinical trials, and regulatory events - scored for significance across 4 global markets.

10+
Sources
4
Markets
12h
Cycle
50+
Keywords
USUKCNEU
Launch Monitor

Methodology Note

The analysis presented for Princes Group PLC is produced using Strategyland's proprietary 7-factor quantitative model, which evaluates each stock across Liquidity, Valuation, Profitability, Solvency, Asset Efficiency, Market Trading, and Technical dimensions. Individual factor scores and the composite rank reflect relative rankings within the FTSE 100 universe — a lower rank number indicates stronger performance in that category.

Underlying financial and market data is sourced from LSEG (London Stock Exchange Group) and processed through our scoring engine. Scores are recalculated as new data becomes available and should be interpreted as a systematic screening output, not a forecast of future share price performance.

This content is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance and factor rankings are not indicative of future results. Please read our Risk Disclaimer before making any investment decisions.

Note: The information provided is not intended as an offer or solicitation for the purchase or sale of any financial instruments but for investor relations purposes only. The aforementioned securities were offered to the public and currently trade on the secondary market at the exchange mentioned above. It is recommended that investors considering investing in any of these notes consult an approved MiFID Financial Advisor prior to investing.